September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Topical Low-Molecular-Weight Heparin-Taurocholate 7 Inhibits Corneal Neovascularization
Author Affiliations & Notes
  • Jae Yong Kim
    Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (the Republic of)
  • Mi Hyun Cheon
    Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (the Republic of)
  • Eun-Soon Kim
    Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (the Republic of)
  • Myoung Joon Kim
    Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (the Republic of)
  • Hungwon Tchah
    Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Jae Yong Kim, None; Mi Hyun Cheon, None; Eun-Soon Kim, None; Myoung Joon Kim, None; Hungwon Tchah, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3517. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jae Yong Kim, Mi Hyun Cheon, Eun-Soon Kim, Myoung Joon Kim, Hungwon Tchah; Topical Low-Molecular-Weight Heparin-Taurocholate 7 Inhibits Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3517.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the antiangiogenic effects and safety of topically applied low-molecular-weight heparin-taurocholate 7 (LHT7) on corneal neovascularization (CoNV).

Methods : Subconjunctival LHT7 injection was reported to attenuate corneal neovascularization (CoNV) after chemical cauterization in a rat model, despite complications that included corneal stromal hemorrhage. Topical applications of LHT7 should be considered to overcome this side effect. Twenty-four Sprague-Dawley rats were divided into four groups of six animals each. Corneal centers were cauterized by application of a silver/potassium nitrate solution. From 2 days after cauterization, 12.5 mg/mL (low LHT7 group) or 25 mg/mL (high LHT7 group) LHT7 was topically administered three times daily; 12.5 mg/mL bevacizumab was topically administered in the positive control (bevacizumab) group, with normal saline administered in the negative control (NS) group. Digital photographs of the cornea were taken 1 and 2 weeks later to calculate the CoNV percentage from the area of neovascularized cornea.

Results : The CoNV percentage did not significantly differ among the four study groups at 1 week after injury (p>0.05). However, the CoNV percentage in the low LHT, high LHT, and bevacizumab groups significantly decreased compared with that in the NS group at 2 weeks (all p<0.05). There were no statistically significant differences in the CoNV among the low LHT, high LHT, and bevacizumab groups (all p>0.05). In all groups except the NS group, the percentage of CoNV decreased at 2 weeks post-injury compared with that observed at 1 week (all p<0.05).

Conclusions : Topically-administered LHT7 inhibited CoNV without complication after chemical cauterization in the rat.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×